NeoGenomicsNEO +0.49%71 Days Inventory is 25.18 as of Mar. 2026, which is 2% above its 10-year median of 24.76. GuruFocus rates NEO with a GF Score™ of 71/100 and a GF Value™ of $16.58 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 176 Medical Diagnostics & Research companies, NeoGenomics ranks better than 80.11% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). NeoGenomics's Average Total Inventories for the
three
months ended in Mar. 2026 was $29.2 Mil. NeoGenomics's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $105.8 Mil.
Hence, NeoGenomics's Days Inventory for the
three
months ended in Mar. 2026 was 25.18.
The historical rank and industry rank for NeoGenomics's Days Inventory or its related term are showing as below:
NEO'
s Days Inventory Range Over the Past 10 Years
Min: 15.51 Med: 24.76 Max: 32.49
Current: 25.96
During the past 13 years, NeoGenomics's highest Days Inventory was 32.49. The lowest was 15.51. And the median was 24.76.
NEO's Days Inventory is ranked better than 80.11% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.88
vs NEO: 25.96
NeoGenomics's Days Inventory
declined
from Mar. 2025 (27.20) to Mar. 2026 (25.18).
Inventory Turnover measures how fast the company turns over its inventory within a year.
NeoGenomics's Inventory Turnover for the
three
months ended in Mar. 2026 was 3.62.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeoGenomics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.16.
NeoGenomics (NAS:NEO) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NeoGenomics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeoGenomics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
NeoGenomics Days Inventory Related Terms
NeoGenomics Days Inventory Historical Data
* Premium members only.
The historical data trend for NeoGenomics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NeoGenomics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeoGenomics Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Days Inventory distribution charts can be found below:
* The bar in red indicates where NeoGenomics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (NEO) has a Days Inventory of 25.18 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NeoGenomics and its competitors. This is near median its historical median of 24.76. Over the past decade, NeoGenomics' Days Inventory has ranged from 15.51 to 32.49. According to the industry distribution chart, NeoGenomics ranks #35 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 19.9%.
Is NeoGenomics' Days Inventory too high?
NeoGenomics' current Days Inventory of 25.18 is near median its 10-year median of 24.76. Over the past 10 years, this metric has ranged from a low of 15.51 to a high of 32.49. The Medical Diagnostics & Research industry median Days Inventory is 68.88. NeoGenomics' value of 25.18 is 63.4% below this industry median. Based on the distribution chart, NeoGenomics ranks #35 out of 176 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Days Inventory compare to WGS and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, NeoGenomics ranks #35 out of 176 companies for Days Inventory. This places NeoGenomics in the top 20% of its industry — outperforming the majority of peers. The industry median Days Inventory is 68.88. NeoGenomics' value of 25.18 is 63.4% below this benchmark. Historically, NeoGenomics' own Days Inventory has ranged from 15.51 to 32.49 over the past decade. While the company's 10-year median is 24.76 vs. the industry median of 68.88, NeoGenomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.88, based on 176 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeoGenomics's current Days Inventory of 25.18 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NeoGenomics and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeoGenomics's current Days Inventory is 25.18, which is near median its own 10-year median of 24.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.58, compared to a current price of $14.24 — trading 14.1% below its estimated fair value. The current Days Inventory is 25.18, which is near median its 10-year median of 24.76 and 63.4% below the Medical Diagnostics & Research industry median of 68.88. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For NeoGenomics (NEO), the current Days Inventory is 25.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of $14.24 is trading 14.1% below its estimated GF Value™ of $16.58.
GuruFocus considers NeoGenomics to be Modestly Undervalued.
Key valuation signals for NEO:
Days Inventory: 25.18 (near median its 10-year median of 24.76)
GF Value™: $16.58 vs. price of $14.24 (14.1% below fair value)
Industry Position: 63.4% below the Medical Diagnostics & Research median (#35 of 176)
No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score
Get the complete analysis for NEO
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEO has been successfully added to your 
